More about

Major Depressive Disorder

News
May 10, 2023
1 min read
Save

Zuranolone effective in major depression

Zuranolone effective in major depression

People with major depressive disorder experienced a significantly greater improvement in symptoms on zuranolone compared with placebo after 2 weeks of treatment, according to findings published in The American Journal of Psychiatry.

News
April 21, 2023
1 min read
Save

Phase 2 data support lysergide for major depressive disorder

Phase 2 data support lysergide for major depressive disorder

A phase 2 trial provided positive results for the use of lysergide, otherwise known as LSD, in major depressive disorder, according to a press release.

News
January 25, 2023
1 min read
Save

First participants dosed in phase 1 study of nasal spray for treatment of MDD

First participants dosed in phase 1 study of nasal spray for treatment of MDD

A biopharmaceutical company announced the first participants have been dosed in its phase 1 clinical trial of PH10, an investigational pherine nasal spray to treat major depressive disorder.

News
January 18, 2023
1 min read
Save

FDA gives tentative approval for extended-release capsules of MDD treatment

FDA gives tentative approval for extended-release capsules of MDD treatment

The FDA has granted tentative approval to Zydus Pharmaceuticals Inc. to market extended-release capsules of levomilnacipran, a treatment for major depressive disorder, the company announced in a press release.

News
January 04, 2023
2 min read
Save

Intervention key for major depressive disorder to prevent treatment-resistant depression

Intervention key for major depressive disorder to prevent treatment-resistant depression

For those with major depressive disorder, early intervention is crucial to address treatment-resistant depression, which may lead to higher disease burden on the patient and health care system, per a study published in JAMA Psychiatry.

News
January 03, 2023
1 min read
Save

Vistagen to acquire Pherin Pharmaceuticals, bolstering plans for therapeutic development

Vistagen announced it has agreed to acquire Pherin Pharmaceuticals Inc., to bolster its efforts on discovery and development of therapeutics to treat a range of psychiatric and neuropsychiatric conditions.

News
December 23, 2022
1 min read
Save

Vistagen receives FDA fast track for nasal spray for major depressive disorder

Vistagen receives FDA fast track for nasal spray for major depressive disorder

The FDA has granted Vistagen fast track designation for PH10, a nasal spray for the treatment of major depressive disorder, according to a company press release.

News
December 15, 2022
6 min watch
Save

VIDEO: Cariprazine effective adjunctive therapy in MDD

VIDEO: Cariprazine effective adjunctive therapy in MDD

In this video, Michael E. Thase, MD, MS, spoke with Healio about his poster presentation from the 2022 NEI Congress regarding clinical trial results on cariprazine for adjunctive treatment of major depressive disorder.

News
December 13, 2022
2 min read
Save

Deep learning may help predict mental disorder diagnosis

Deep learning may help predict mental disorder diagnosis

A multidiagnostic prediction model developed using deep learning was highly predictive of mental disorder diagnosis, according to new data published in JAMA Psychiatry.

News
December 08, 2022
1 min read
Save

Sage, Biogen submit NDA for depression treatment

Sage, Biogen submit NDA for depression treatment

Pharmaceutical company Sage Therapeutics and biotech firm Biogen announced completion of a rolling submission of a new drug application to the FDA for zuranolone for the treatment of major depressive disorder and postpartum depression.

View more